# Apnar Pharma Private Limited – FDA 483, Sep 11, 2026

Source: https://www.keypedia.com/records/483/apnar-pharma-private-limited/798177ba-2593-402f-b9bf-17de66f862da

> FDA 483 for Apnar Pharma Private Limited on September 11, 2026. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Apnar Pharma Private Limited
- Inspection Date: 2026-09-11
- Product Type: drugs
- Office Name: Office of Inspections and Investigations
- Summary: An FDA inspection of Apnar Pharma Private Limited in Padra, India, revealed a significant deficiency in their systems for complying with the Drug Supply Chain Security Act (DSCSA). The firm lacked adequate procedures for verifying product, responding to illegitimate product notifications, identifying suspect products, and maintaining required records. This indicates a critical failure in ensuring the security and traceability of their drug supply chain.

## Related Documents

- [483 - 2022-09-16](https://www.keypedia.com/records/483/apnar-pharma-private-limited/21970f91-94f2-4c0c-a8bd-3243ea784bde) — date: September 16, 2022

## Related Officers

- [Tanya R. Syffrard](https://www.keypedia.com/people/tanya-r-syffrard/a78a42b3-6cef-46d9-9698-ec6082956477)

Company: https://www.keypedia.com/companies/apnar-pharma-private-limited/14c28e0f-fd47-4c3a-80c3-f85e25d7ea0a

Office: https://www.keypedia.com/offices/office-of-inspections-and-investigations/7dd0b904-a3df-46bc-a7b2-70ddb6f809c8